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Letters e211the buttocks, axillae, and groins and evolved in
crops. Besides these nodules, physical examination
revealed bridged scars, but no interconnecting
tracts. Histologic examination of a skin biopsy and
cultures ruled out Crohn disease and an opportu-
nistic infection, respectively. The diagnosis was
HS grade II according to the Hurley classification. A
6-month course of oxacillin (2 g/day), followed by a
combination of rifampicin (600 mg/day) with
clindamycin (600 mg/day) for 9 months were
ineffective (Fig 1). In February 2012, Cs was
replaced with tacrolimus (2 mg/day) based on
the hypothesis of a deleterious effect of Cs on
pilosebaceous apparatus and of a potential efficacy
of tacrolimus as suggested in another report.2
In November 2012, all inflammatory lesions had
disappeared (Fig 2).
To our knowledge, this patient is the first case of
HS appearing in the setting of organ transplantation.
Although a fortuitous association cannot be
excluded, considering the patient’s age, the clinical
scenario speaks in favor of an iatrogenic origin of HS.
Indeed, rare cases of iatrogenic HS have been
reported.3 Even if several Cs-responsive cases of
HS exist,4 Cs is known to induce hyperplasia of the
pilosebaceous apparatus.5 Isotretinoin may also
have played an aggravating role. This patient is
similar to one suffering from HS for more than
20 years, in whom treatment with Cs had been
ineffective.2 He was cured at the age of 40 years,
a few months after kidney transplantation, while
receiving tacrolimus and mycophenolate mofetil
as immunosuppressive treatment. We recently
observed another case of HS that appeared within
2 years after transplantation, for which we suggested
a switch from Cs to tacrolimus. Although tacrolimus
and Cs exert very similar immunosuppressive effects,
the former proved more effective than the latter
against HS in these cases. This may be due to the
fact that tacrolimus exerts fewer effects on the
pilosebaceous apparatus.
This observation suggests that patients in whom
HS develops while on Cs should be switched to
tacrolimus.
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Ipilimumab-associated Sweet syndrome in a
melanoma patient
To the Editor: We read with interest the recently
published letter ‘‘Ipilimumab-associated Sweet syn-
drome in a patient with high-risk melanoma,’’1 in that
we had a patient with a very similar presentation. A
57-year-old man with stage IIIC (T4b, N3, cM0)
melanoma was enrolled in a phase 3 randomized
study of adjuvant ipilimumab. Eleven days after his
first infusion of ipilimumab, he presented to his
oncologist with an itchy rash. He was on no other
new medications and denied fever, diarrhea,
myalgias, or other systemic symptoms.
The patient subsequently presented to the
dermatology service 6 weeks after his first dose of
ipilimumab with widespread erythematous, edema-
tous papules and plaques, some with pseudovesic-
ular appearance, and scattered pustules on the face,
trunk, arms, and dorsal hands (Fig 1). At the time of
evaluation, there was no evidence of melanoma
progression. Complete blood count was within
normal limits without peripheral neutrophilia. Skin
biopsies were performed and demonstrated promi-
nent papillary dermal edema with extensive neutro-
philic infiltrate extending to the subcutaneous tissue
with scattered eosinophils and plasma cells (Fig 2).
The histopathologic features were consistent with
Sweet syndrome (SS). The patient was treated with
oral prednisone, initial dose of 60 mg daily, with
rapid improvement. Prednisone was subsequently
Fig 1. Sweet syndrome. Erythematous and edematous
papules and plaques were noted over the trunk, legs, arms,
and dorsal hands, some with a pseudovesicular appearance.
Views of pseudovesicular lesions on the dorsal hand.
Fig 2. Sweet syndrome. Histopathology demonstrated
spongiosis and prominent papillary dermal edema with a
predominantly neutrophilic infiltrate. The inflammatory
infiltrate also consisted of many eosinophils with scattered
lymphocytes and histiocytes. Periodicacid Schiff
and acid-fast bacilli stains were negative for organisms
(not shown). (Hematoxylin and eosin stain; original
magnification: 340.)
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lesions. He was not re-treated with ipilimumab.
Ipilimumab has been associated with immune-
related inflammatory toxic effects in 80% of patients,
including enterocolitis, hepatitis, dermatitis, neurop-
athy, and endocrinopathy.2 Ipilimumab-related
dermatitis is generally observed within 3 to 4 weeks
of starting therapy, often reported as a ‘‘maculopap-
ular rash’’ (47% to 68% of patients).2More specific reports of adverse dermatologic
effects range from milder entities, such as vitiligo and
alopecia, tomore severe conditions including Stevens-
Johnson syndrome and toxic epidermal necrolysis.2,3
The histopathologic characteristics of ipilimumab-
related dermatitis are not yet well-characterized.
The few existing reports describe an interface
dermatitis (composedofpredominatelyCD81Tcells),
perivascular inflammation, and increased mucin
deposition in thepapillary and reticular dermis, similar
to cutaneous lupus erythematosus.4
Outside of the report by Kyllo et al,1 there was a
case of SS in association with ipilimumab observed
in a study patient being treated for metastatic
ovarian cancer who was receiving ipilimumab as
part of a sequential immunotherapy protocol
involving vaccination with autologous tumor cells
engineered to secrete granulocyte macrophage
colony-stimulating factor (GM-CSF).4 However, in
this case it is difficult to definitively determine the
individual contributions of the patient’s solid
ovarian malignancy, vaccination with subsequent
GM-CSF production, and/or ipilimumab treatment to
development of SS.
We present another case of SS in a patient with
melanoma, temporally related to ipilimumab treat-
ment, which strengthens the potential association.
Although difficult to know whether SS occurred as
a paraneoplastic phenomenon triggered by the
patient’s underlying melanoma, as has been once
previously reported in the Spanish literature, the
timing and onset of SS 11 days after his first dose
of ipilimumab, lack of tumor progression, and
improvement off the medication suggest ipilimumab
as the trigger.5 As ipilimumab treatment for
melanoma becomes more widespread, it is
important for clinicians to be aware of the potential
for development of SS.
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Fig 1. Disseminated cutaneous leishmaniasis in patient
with Sezary syndrome. Erythematous papulonodules on
the trunk.
Fig 2. Disseminated cutaneous leishmaniasis in patient
with Sezary syndrome. Large numbers of Leishmania
amastigotes within the macrophages (arrows). (Hematox-
ylin and eosin; original magnification: 3640.)
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Disseminated cutaneous leishmaniasis in a
patient with Sezary syndrome
To the Editor: A 66-year-old Caucasian man was
diagnosed with Sezary syndrome (SS) in 2007.
After chlorambucil, prednisone, and bexarotene
treatment, only a partial response was achieved.
In May 2012, he was hospitalized with necrotizing
pneumonia. He presented with typical features of SS:
erythroderma, pruritus, and enlarged lymph nodes.
Laboratory studies showed total leukocytes
8.2 3 109/L (normal range: 4-11 3 109/L), 84.5%
neutrophils, and 8.2% lymphocytes, of which 35%
were Sezary cells. Increased lactate dehydrogenase,
520 U/L (normal range: 250-450 U/L), was also seen.
The patient had numerous asymptomatic
hyperpigmented macules on his trunk and limbs,
which appeared over the previous 6 months.
Histopathologic examination of lesions showed
acanthosis, epidermotropism, and a mild perivascu-
lar atypical lymphoid infiltrate in the upper dermis.
Lymphocytes were hyperchromatic, with indented
cerebriform nuclei, and expressed CD2, CD3, CD4,
and CD5, with partial loss of CD7.
Five months later, the patient was readmitted
with fever, malaise, and progression of skin lesions.
Cutaneous examination revealed numerous wide-
spread erythematous papules and nodules (Fig 1). Askin biopsy showed a dense lymphohistiocytic
infiltrate in the upper and middle dermis with intra-
cellular microorganisms suggestive of Leishmania
amastigotes (Fig 2). Disseminated cutaneous leish-
maniasis was diagnosed and confirmed by positive
polymerase chain reaction for Leishmania infantum.
Bone marrow aspirate was negative for Leishmania.
Liposomal amphotericin B (4 mg/kg/day intrave-
nously) was given for 10 days without clinical
improvement, so treatment was switched to meglu-
mine antimonate (20 mg/kg/day intravenously).
After the first dose, the patient’s condition worsened;
fever and flare of cutaneous lesions developed.
Jarisch-Herxheimer reaction was diagnosed and the
